New Release: Alpha testing version has been released.

Isosorbide

C01D - Vasodilators used in cardiac diseases ATC C01DA08 Small molecule approved 1974 Oral Natural product

JFDA label: ISOCARD 10mg TAB.

Mechanism of Action

— Osmotic agent

Indications

Approved

  • Angina pectoris, prevention

Off-label

  • Esophageal spastic disorders
  • Heart failure with reduced ejection fraction (intolerance to an ACE inhibitor or an angiotensin receptor blocker)
  • Heart failure with reduced ejection fraction, NYHA Class III-IV (African-American [self-identified] patients)

Contraindications

Source: Lexicomp

  • Additional contraindications (not in US labeling): Cardiogenic shock or risk of cardiogenic shock developing Absolute
  • Hypersensitivity to isosorbide dinitrate or any component of the formulation Absolute
  • concurrent use with phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil, or avanafil) Absolute
  • concurrent use with riociguat Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Cardiac disorders (5)

Not Known Hypotension · orthostatic hypotension · rebound hypertension (uncommon) · syncope (uncommon) · unstable angina pectoris (uncommon)

Nervous system disorders (2)

Not Known Dizziness (related to blood pressure changes) · headache (most common)

Blood and lymphatic system disorders (1)

Not Known Methemoglobinemia (rare; overdose)

Dosing

Source: Lexicomp

Angina pectoris (prevention): Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode. Tolerance to nitrate effects develops with chronic exposure; dose escalation does not overcome this effect. Tolerance can only be overcome by short periods of nitrate absence from the body. Nitrate-free intervals of ≥14 hours (immediate release products) or >18 hours (sustained release products) may help minimize tolerance. Oral: Immediate release: Initial: 5 to 20 mg 2 to 3 times daily; Maintenance: 10 to 40 mg 2 to 3 times daily or 5 to 80 mg 2 to 3 times daily (Anderson 2011) Sustained release: 40 to 160 mg/day has been used in clinical trials (a nitrate free interval of >18 hours is recommended; however, a clinically efficacious dosage interval has not been clearly established) or 40 mg 1 to 2 times daily (Anderson 2011). Maximum dose: 160 mg/day (Dilatrate-SR only). Sublingual [Canadian product]: 5 to 10 mg every 2 to 4 hours for prophylaxis of acute angina; may supplement with 5 to 10 mg prior to activities which may provoke an anginal episode. Heart failure (off-label use; ACCF/AHA [Yancy 2013]): Oral: Immediate release (Note: Use in combination with hydralazine): Initial dose: 20 to 30 mg 3 to 4 times daily Maximum dose: 120 mg daily in divided doses Esophageal spastic disorders (off-label use; Goyal, 1998): Oral, sublingual: Immediate release: 10 to 30 mg before meals
Elderly patients should be given lowest recommended adult daily doses initially and titrate upward. Refer to adult dosing.

Warnings & Precautions

Source: Lexicomp

Hypotension/bradycardia

Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Orthostatic hypotension can also occur; ethanol can accentuate this. Use with caution in volume depletion and hypotension, and use with extreme caution with inferior wall MI and suspected right ventricular infarctions. Severe hypotension, particularly with upright posture, may occur with even small doses.

Intracranial pressure increased

Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008). Disease-related concerns:

Cardiovascular disease

Not recommended in patients with acute MI or HF (cannot easily reverse effects if adverse events develop).

Hypertrophic cardiomyopathy (HCM)

Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (ACCF/AHA [Gersh 2011]). Concurrent drug therapy issues:

Drug-drug interactions

Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Other warnings/precautions:

Tolerance

Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect. When used for HF in combination with hydralazine, tolerance is less of a concern (Gogia 1995).

Pregnancy & Lactation

Pregnancy

FDA category C

Adverse events have been observed in some animal reproduction studies. Nitric oxide donors, such as isosorbide, have been evaluated for pre-eclampsia and cervical ripening; isosorbide dinitrate use in these conditions is not currently recommended (Kalidindi 2012; Ramirez 2011).

Lactation

It is not known if isosorbide dinitrate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering isosorbide dinitrate to nursing women.

Monitoring

Clinical pearlBlood pressure, heart rate

Chemistry & Properties

2D structure
FormulaC6H10O4
Molecular weight146.14 g/mol
IUPAC name(3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol
CAS652-67-5
PubChem CID12597
InChIKeyKLDXJTOLSGUMSJ-JGWLITMVSA-N
logP-1.49 (XLogP -1.4)
Polar surface area58.92 Ų
H-bond acceptors / donors4 / 2
Drug-likeness (QED)0.44
Lipinski violations0
SMILESO[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability70.0%
Half-life2.732 h
Volume of distribution0.594 L/kg
Protein binding6.8%
BBB penetrantNo

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Drug–drug interactions (30, DDInter)

Interacting drugSeverityManagement
Nitrous acid major
Alimemazine moderate
Amifostine moderate
Benzocaine (topical) moderate
Brimonidine (ophthalmic) moderate
Brimonidine (topical) moderate
Cinchocaine (topical) moderate
Cocaine (nasal) moderate
Cocaine (topical) moderate
Epoprostenol moderate
Iloprost moderate
Irinotecan moderate
Irinotecan (liposomal) moderate
Lidocaine (ophthalmic) moderate
Lidocaine (topical) moderate
Methdilazine moderate
Minoxidil (topical) moderate
Oxybuprocaine (ophthalmic) moderate
Ozanimod moderate
Pentoxifylline moderate
Procarbazine moderate
Promethazine moderate
Rosiglitazone moderate
Selexipag moderate
Tetracaine (ophthalmic) moderate
Tetracaine (topical) moderate
Thiethylperazine moderate
Treprostinil moderate
Demeclocycline minor
Doxycycline minor

Registered Products (16)

BrandForm / strengthPackAgentCitizen (JOD)
Isoket Tablet Tablet 5 mg 50 tab pack varies Suleiman Tannous & Sons Co. Ltd 1.890
ISOCARD 10mg TAB. Tablet 10 mg 100 tab pack varies Dar Al Dawa Development and Investment Co Ltd/Jordan 2.300
Cardipine 5 Sublingual Tablets Tablet 5 mg 100 tab Hikma Pharmaceuticals Co.Ltd/Jordan 2.400
Isoket Retard Tablet Tablet 20 mg 50 tab Suleiman Tannous & Sons Co. Ltd 2.790
ISORDIL SUBLINGUAL tabs Tablet 5 mg 100 tab Arab Company for Medical & Agricultural Products 2.870
ISORDIL TAB. Tablet 10 mg 100 tab Arab Company for Medical & Agricultural Products 2.870
Isobide Capsule 40 mg 20 cap Khoury Drug Store 3.000
Isobide Capsule 20 mg 20 cap Khoury Drug Store 3.000
Isoket Tablet Tablet 10 mg 100 tab Suleiman Tannous & Sons Co. Ltd 3.640
Isoket Tablet Tablet 5 mg 100 tab pack varies Suleiman Tannous & Sons Co. Ltd 3.640
Isosorbide Dinitrate Tablet 20 mg 100 tab مستودع أدوية الليليو٠3.710
Isoket Retard Tablet Tablet 40 mg 50 tab Suleiman Tannous & Sons Co. Ltd 4.780
ISORDIL TAB Tablet 30 mg 100 tab Arab Company for Medical & Agricultural Products 5.580
Isosorbide Dinitrate Tablet 40 mg 100 tab مستودع أدوية الليليو٠6.080
ISOCARD 10 mg TABS. Tablet 10 mg 500 tab pack varies Dar Al Dawa Development and Investment Co Ltd/Jordan 10.580
Isoket Ampules I.V. Ampoule 0.1 %[1 mg/ml] 10 amp Suleiman Tannous & Sons Co. Ltd